ARMP: Armata Pharma Company Value to Net Income

Corporate emblem and logo of Armata Pharma (ARMP)

Armata Pharmaceuticals (ARMP) occupies a unique niche in biopharmaceuticals, developing agents against superbugs under strict patent protection. This price chart illustrates the asset's dynamics, where the P/E ratio stands at -0.70. The business relies on a personalized approach to pathogen eradication. Currently, Armata Pharmaceuticals (ARMP) is scaling its R&D platform, aiming to complete mid-stage trials with the support of major investment funds.

P/E Multiple: Armata Pharmaceuticals, Inc. (ARMP) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Armata Pharmaceuticals

- price and consensus price forecast:
Stock Price armatapharma.com|ARMP - Consensus Target
- market capitalization information:
Market Value Armata Pharmaceuticals, Inc.|ARMP - Total Company Value
- balance sheet net asset value indicators:
Accounting Value per Share Armata Pharmaceuticals|ARMP - Book Capitalization|Market Capitalization to Book Value armatapharma.com|ARMP - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Equity Ratio Armata Pharmaceuticals|ARMP - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Armata|ARMP - Company Debts|Debts to Book Value Armata Pharmaceuticals, Inc.|ARMP - Company Long-Term Debts|Company Short-Term Debt Armata Pharmaceuticals|Immediate Liquidity armatapharma.com
- company profitability and valuation multiples indicators:
ARMP - Company Net Income|Company Profit Forecast Armata Pharmaceuticals|ARMP - P/E Multiple|Forward P/E Multiple Armata Pharmaceuticals Inc|ARMP - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Armata Pharmaceuticals, Inc.|ARMP - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Armata Pharmaceuticals|ARMP - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth armatapharma.com|ARMP - Net earnings per share growth this year|Projected earnings per share increase next year Armata Pharmaceuticals
Comprehensive company analysis:ARMP (armatapharma.com)
Signature product of Armata

The success of Armata Pharmaceuticals (ARMP) depends on the effectiveness of developing phage therapies to combat resistant lung pathogens. This potential is capitalized through the ratio of the stock's market price to the net earnings per share. This metric determines the investment payback period, accounting for tax adjustments and government subsidies. By analyzing the issuer's P/E ratio, an investor can identify if the asset is overbought and avoid the risk of an overvaluation of the business.

Key competitors

P/E Multiple Acurx